AMRA-MEDICAL
10.4.2024 16:57:33 CEST | Business Wire | Press release
Researchers from AMRA Medical, a leading health informatics company providing body composition analysis through magnetic resonance imaging (MRI), together with Eli Lilly, and researchers from Nantes Université, University Hospitals Cleveland, and Linköping University used visceral-, subcutaneous-, and liver fat z-scores derived from MRI to investigate changes in fat distribution patterns in patients with type 2 diabetes (T2D) participating in SURPASS-3 MRI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410636011/en/
AMRA Medical's Personalized Fat Z-scores (Photo: Business Wire)
Absolute (or percent) change in body weight and/or BMI are still typical endpoints in clinical trials evaluating treatments for obesity and related disorders. However, the research team’s recent findings from the SURPASS-3 MRI study suggest that pharmacological treatments for T2D may alter the fat distribution pattern in various ways - independent of changes in body weight. For this reason, fat distribution profiling through personalized z-score assessment would represent an attractive and modifiable endpoint for future therapeutic efficacy trials in obesity and related disorders.
The personalized fat z-scores were introduced through research published in 2023 linking fat distribution patterns, as described by the z-scores, to specific cardiometabolic disease risk profiles in the general population. This was quickly followed by Surgery for Obesity and Related Diseases (SOARD) publishing results on risk-stratification of obesity class I & II by the fat z-scores in the American Society for Metabolic and Bariatric Surgery (ASMBS) guidelines/statements journal section of SOARD. (Read more about z-score use in risk-stratification here).
The current exploratory analysis of data from Lilly’s SURPASS-3 MRI study, described changes in the fat z-scores in people with T2D following treatment with once-weekly tirzepatide (5, 10 or 15 mg dose) or once-daily basal insulin degludec for 52 weeks. The results showed that treatment with tirzepatide was associated with a significant reduction in visceral fat z-score (-0.18 SD) and liver fat z-score (-0.54 SD), while the subcutaneous fat z-score increased from an initially negative value (+0.11 SD) - suggesting a therapeutically-induced shift towards a better-balanced body fat distribution with prominent visceral and liver fat loss.
During follow-up of interventions that induce weight reduction, it has been difficult to determine whether a concurrent reduction of, e.g., visceral fat was in line with the amount of weight lost, or if there was larger reduction than expected. The significant reduction of visceral fat and liver fat z-scores observed with tirzepatide in SURPASS-3 MRI indicates a potential targeted effect beyond that expected by the magnitude of weight reduction.
Read the full publication titled ‘Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes’ here.
About AMRA Medical
AMRA Medical is a health informatics company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition analysis, delivering multiple fat and muscle biomarkers with unrivalled accuracy and precision – all from a rapid whole-body MRI scan. AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.
Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions or connect with our team of experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410636011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem20.10.2026 14:00:00 CEST | Press release
Process Context for Enterprise AI provides vital business understanding for the AI ecosystem – helping enterprises unlock greater AI value, fasterNew capabilities improve operational performance, identify where AI can deliver the most value and give agents access to trusted process contextCombines Object-Centric Process Mining (OCPM), Process Lens and Model Context Protocol (MCP) to create essential platform for agentic AI at scale ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value. While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehen
Visa, BILL and Billtrust Launch First Live Pilot for Trusted AI Agent Payments Between Buyer and Supplier Platforms20.10.2026 14:00:00 CEST | Press release
Demonstrates how trusted AI agents are moving beyond automation to act on behalf of buyers and suppliers in real-world commercial transactions. Visa (NYSE: V), BILL (NYSE: BILL) and Billtrust today announced they have launched the first live pilot to enable trusted AI agents to initiate and complete approved buyer invoice payments end-to-end through supplier portals. Until now, many payment portals relied on human authentication requirements that limited how approved payments could be automated. Together, with leading accounts payable and receivable solutions providers BILL and Billtrust, the Visa Intelligent CommerceTM portfolio helps bridge that gap. Leveraging offerings such as Visa Trusted Agent Protocol, AI agents can now be securely authenticated to credentialed portals. As a result, buyer payments that previously relied on manual entry can be completed by trusted AI agents, while preserving supplier control and oversight. How trusted AI agents are overcoming one of payment autom
Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility20.10.2026 14:00:00 CEST | Press release
New modular platform gives researchers greater control over sample and cell throughput while optimizing value Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode™ MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using the same instrument-free workflow, researchers can profile up to 2.5 times as many cells across up to twice as many samples within their existing budget, or run the same experiment at roughly half the overall cost. Evercode MAX enables researchers to build a kit configuration around their experiment, with sample barcoding and library preparation as independent kits. Evercode MAX is available for Whole Transcriptome, WT FFPE, TCR, BCR, and CRISPR Detect. With configurations supporting up to 384 samples and 2 million cells, researchers can prioritize more samples to characterize biological variation or more cells per s
Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation20.10.2026 14:00:00 CEST | Press release
Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/ Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will i
FiRa Consortium Launches Core 4.1 Specifications and Enhanced Certification Program20.10.2026 14:00:00 CEST | Press release
FiRa Core 4.1 expands secure, private, and interoperable FiRa deployments. The FiRa® Consortium today announced the release of the FiRa Core 4.1 Specifications and an updated 4.1 Certification Program to help advance ultra-wideband (UWB) interoperability within the FiRa ecosystem. Core 4.1 introduces enhancements for FiRa Untracked Navigation, expanded cryptographic security certification, and additional support for concurrent ranging and data capabilities across multi-vendor FiRa deployments. The release supports deployment requirements defined by the FiRa Frameworks and Profiles Sub-Group (FPSG), including high-density indoor positioning, hardware-level security, and concurrent data capabilities for FiRa use cases. Features of the FiRa Core 4.1 Specifications and Certification ProgramEnhanced Downlink Time Difference of Arrival (DL-TDoA) for FiRa Untracked Navigation — Adds coordinate-system and anchor-location encoding options, including floor identification without increasing messa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom